Cite
HARVARD Citation
Spyropoulos, A. et al. (2019). Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clinical and applied thrombosis/hemostasis. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Spyropoulos, A. et al. (2019). Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clinical and applied thrombosis/hemostasis. p. . [Online].